Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2026 17:15 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS)...
May 20, 2026 14:38 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system...
May 20, 2026 07:38 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May ...
April 07, 2026 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board

New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable...
March 31, 2026 12:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences to Present at Emerging Growth Conference on April 2

JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented...
February 25, 2026 08:30 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and...
February 23, 2026 09:30 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:...
January 28, 2026 06:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc....
December 23, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6

Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented...
December 03, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum

Company advances JOTROL™ into Phase 2a Parkinson’s trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter...